Galactosylated Chitosan Oligosaccharide Nanoparticles for Hepatocellular Carcinoma Cell-Targeted Delivery of Adenosine Triphosphate
Galactosylated Chitosan Oligosaccharide Nanoparticles for Hepatocellular Carcinoma Cell-Targeted Delivery of Adenosine Triphosphate
复制标题
半乳糖化壳寡糖纳米颗粒用于肝细胞癌细胞靶向递送三磷酸腺苷
DOI：
10.3390/ijms140815755
复制
发表时间：
2013-07
影响因子：
5.6
通讯作者：
Fang Fang Huang
中科院分区：
文献类型：
--
作者：
Dan Shi;Ying Chen;Ying Wang;Fang Fang Huang
制备了半乳糖基化壳寡糖（Gal-CSO）/三磷酸腺苷（ATP）纳米粒，并对纳米粒的性质进行了评价。制备CSO/ATP纳米颗粒作为对照。Gal-CSO/ATP纳米粒的平均粒径和zeta电位分别为51.03 ± 3.26 nm和30.50 ± 1.25 mV，表明其适合于药物递送系统。采用MTT法检测Gal-CSO/ATP纳米粒的细胞毒性，并计算其对人肝癌细胞株HepG 2的半数抑制浓度（IC 50）。结果表明，纳米粒对HepG 2细胞的细胞毒作用较弱。同时，还发现Gal-CSO/ATP纳米颗粒可以被HepG 2细胞摄取，这是由于其表面上表达脱唾液酸糖蛋白受体（ASGP-R）。结果表明，Gal-CSO纳米粒有望成为肝癌细胞靶向给药的细胞内药物载体，为进一步的体内或临床研究奠定了基础。
Nanoparticles composed of galactosylated chitosan oligosaccharide (Gal-CSO) and adenosine triphosphate (ATP) were prepared for hepatocellular carcinoma cell-specific uptake, and the characteristics of Gal-CSO/ATP nanoparticles were evaluated. CSO/ATP nanoparticles were prepared as a control. The average diameter and zeta potential of Gal-CSO/ATP nanoparticles were 51.03 ± 3.26 nm and 30.50 ± 1.25 mV, respectively, suggesting suitable properties for a drug delivery system. Subsequently, the cytotoxicity of Gal-CSO/ATP nanoparticles were examined by the methyl tetrazolium (MTT) assay, and the half maximal inhibitory concentration (IC50) values were calculated with HepG2 (human hepatocellular carcinoma cell line) cells. The results showed that the cytotoxic effect of nanoparticles on HepG2 cells was low. In the meantime, it was also found that the Gal-CSO/ATP nanoparticles could be uptaken by HepG2 cells, due to expression of the asialoglycoprotein receptor (ASGP-R) on their surfaces. The presented results indicate that the Gal-CSO nanoparticles might be very attractive to be used as an intracellular drug delivery carrier for hepatocellular carcinoma cell targeting, thus warranting further in vivo or clinical investigations.
登录
查看更多内容
影响因子：
8
作者：
O'Farrell N;Houlton A;Horrocks BR
通讯作者：
Horrocks BR
用于肝脏靶向治疗的不溶性抗癌药物半乳糖基化纳米晶体：体外评估
影响因子：
5.5
作者：
Wei, Wei;Yue, Zhan-Guo;Ma, Guang-Hui
通讯作者：
Ma, Guang-Hui
影响因子：
2.5
作者：
Zhuoli Zhang;Junxia Li;Shengyong Wu;Y. Liu;Z. Fan;Xiangzhi Zhou;Haitao Zhao;Debiao Li;Y. Huan
通讯作者：
Zhuoli Zhang;Junxia Li;Shengyong Wu;Y. Liu;Z. Fan;Xiangzhi Zhou;Haitao Zhao;Debiao Li;Y. Huan
影响因子：
13.5
作者：
Corbin, IR;Buist, R;Minuk, GY
通讯作者：
Minuk, GY
影响因子：
5
作者：
Bhattacharjee, Sourav;Ershov, Dmitry;Marcelis, Antonius T. M.
通讯作者：
Marcelis, Antonius T. M.